Boston Scientific Corporation $BSX Stock Holdings Raised by Egerton Capital UK LLP

Egerton Capital UK LLP boosted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 223.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,312,504 shares of the medical equipment provider’s stock after acquiring an additional 3,671,548 shares during the period. Boston Scientific accounts for about 5.5% of Egerton Capital UK LLP’s holdings, making the stock its 6th biggest position. Egerton Capital UK LLP owned 0.36% of Boston Scientific worth $518,660,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. FWL Investment Management LLC bought a new position in shares of Boston Scientific in the second quarter worth $26,000. Steph & Co. bought a new position in Boston Scientific in the 3rd quarter worth about $25,000. Murphy & Mullick Capital Management Corp raised its holdings in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 170 shares in the last quarter. Financial Consulate Inc. bought a new stake in shares of Boston Scientific during the 3rd quarter valued at about $25,000. Finally, United Community Bank grew its holdings in shares of Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is owned by insiders.

Analysts Set New Price Targets

BSX has been the topic of a number of recent analyst reports. Stifel Nicolaus lowered their target price on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Wednesday, February 4th. BTIG Research restated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, February 4th. Royal Bank Of Canada cut their target price on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. TD Cowen lowered their price target on Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Finally, UBS Group cut their target price on Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a research note on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $108.36.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Street sentiment and recent analyst commentary lean favorable after the company’s quarterly results and guidance; the board added Cathy Smith and Christophe Weber, which investors view as governance/strategic strengthening. What Does the Street Think About Boston Scientific Corporation (BSX)?
• Positive Sentiment: Boston Scientific arranged multiple credit facilities totaling roughly $11 billion, boosting liquidity and providing financial flexibility for M&A, R&D, or share-repurchase plans — a constructive sign for risk management and capital strategy. Boston Scientific enters into multiple credit facilities totaling $11B
• Positive Sentiment: Management promoted an internal candidate to president of Vascular Therapies, signaling leadership continuity and succession depth in a key growth division. Boston Scientific promotes new president of Vascular Therapies from within
• Neutral Sentiment: Market coverage notes BSX is “trending” and trading up relative to the broader market on the session, driven partly by investor interest after earnings — useful for short-term flows but not a fundamental change. Boston Scientific (BSX) Ascends While Market Falls: Some Facts to Note
• Neutral Sentiment: Commentary points out BSX has trailed the Dow over recent periods despite analyst optimism — flags for investors focused on relative performance and timing for rotation into healthcare. Is Boston Scientific Stock Underperforming the Dow?
• Negative Sentiment: FDA-linked reporting: Boston Scientific halted use of certain AXIOS stent delivery devices after deployment issues associated with 167 injuries and three deaths — a material product-safety concern that can affect revenue, litigation exposure and reputation in the short-to-medium term. Boston Scientific Halts Use Of Select Stent Delivery Devices After Patient Deaths
• Negative Sentiment: An investor law firm (Pomerantz) has opened an investigation into claims on behalf of BSX investors, increasing legal risk and potential headline volatility. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation – BSX

Boston Scientific Trading Up 1.2%

NYSE:BSX opened at $76.68 on Friday. The firm has a market capitalization of $113.78 billion, a P/E ratio of 39.52, a P/E/G ratio of 1.05 and a beta of 0.67. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The company has a fifty day moving average of $87.31 and a 200 day moving average of $95.65. Boston Scientific Corporation has a 52 week low of $72.69 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.